Department of Medicine, University of Toledo College of Medicine & Life Sciences, Toledo, OH 43614, USA.
ProMedica Health System, Toledo, OH 43606, USA.
Future Oncol. 2020 Mar;16(9):483-495. doi: 10.2217/fon-2019-0722. Epub 2020 Feb 26.
Given recent advances in cancer immune therapy, specifically use of checkpoint inhibitors, understanding the link between autoimmunity and cancer is essential. Rheumatoid arthritis (RA) affects about 1% of the population, and early diagnosis is key to prevent joint damage. Management consists of disease-modifying antirheumatic drugs that alter normal immunologic pathways, which could affect malignancy growth and survival. Prolonged immune dysregulation and the resulting inflammatory response associated with development of RA may also lead to increased cancer development risk. RA has long been associated with increased risk of non-Hodgkin's lymphoma [1] and further evidence supports relationship to lung cancer [2]. This review will address the mechanisms behind cancer development and progression in RA patients, biomarkers and assess cancer risk and early detection.
鉴于癌症免疫疗法的最新进展，特别是检查点抑制剂的应用，了解自身免疫与癌症之间的联系至关重要。类风湿关节炎（RA）影响约 1%的人口，早期诊断是预防关节损伤的关键。治疗包括改变正常免疫途径的疾病修饰抗风湿药物，这可能会影响恶性肿瘤的生长和存活。RA 相关的长期免疫失调和由此产生的炎症反应也可能导致癌症发展风险增加。RA 一直与非霍奇金淋巴瘤[1]的风险增加有关，进一步的证据支持与肺癌[2]的关系。本综述将探讨 RA 患者癌症发展和进展的背后机制、生物标志物以及评估癌症风险和早期检测。
